Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Tax Provisions data on file, last reported at $1.0 million in Q1 2026.

• Tax Provisions for Q1 2026 came in at $1.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 4.09% YoY), and the FY2025 annual result was $4.0 million, up 33.33% from the prior year.
• Tax Provisions grew to $1.0 million in Q1 2026 per RARE's latest filing, from $870000.0 in the prior quarter.
• Over five years, Tax Provisions peaked at $6.3 million in Q3 2022 and troughed at -$3.9 million in Q4 2023.
• A 5-year average of $766235.3 and a median of $732000.0 in 2023 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2022 and 2023: Tax Provisions jumped 3354.4% in 2022, then sank 2151.32% in 2023.
• A 5-year view of Tax Provisions shows it stood at $189000.0 in 2022, then slumped by 2151.32% to -$3.9 million in 2023, then soared by 135.7% to $1.4 million in 2024, then tumbled by 37.14% to $870000.0 in 2025, then increased by 14.94% to $1.0 million in 2026.
• Business Quant data shows RARE's Tax Provisions at $1.0 million in Q1 2026, $870000.0 in Q4 2025, and $873000.0 in Q3 2025.